Advertisement
AZTA vs RVTY
Which Stock Would AI Choose? Azenta, Inc. (AZTA) vs. Revvity, Inc. (RVTY) Stock Comparison
Key Takeaways
- Azenta (AZTA) reported Q2 FY2026 revenue of $145 million, down 3% organically, with lowered full-year guidance amid North American demand softness and impairments.
- Revvity (RVTY) delivered Q1 2026 revenue of $711 million, up 7% year-over-year and 3% organically, beating estimates on diagnostics strength.
- AZTA shares have declined sharply YTD (~26%) and over one year (~3%), reflecting execution challenges, while RVTY shows relative stability with ~10% YTD drop but positive quarterly momentum.
- Both operate in life sciences, but RVTY benefits from broader diagnostics exposure and higher recurring revenue, contrasting AZTA's sample management focus amid capital spending caution.
- Tickeron's AI tools highlight sector trends; explore Trending AI Robots for pattern-based insights.
- Market positioning favors RVTY on growth consistency, though both face life sciences sector headwinds.
Introduction
Azenta, Inc. (AZTA) and Revvity, Inc. (RVTY) are key players in the life sciences sector, providing essential tools for drug development, sample management, and diagnostics. This stock comparison evaluates their recent performance, business models, and market dynamics amid cautious capital spending and evolving demand in biopharma and healthcare. Traders seeking short-term momentum and investors focused on relative performance in healthcare tools will find value in understanding contrasts in revenue growth, segment resilience, and sentiment shifts. With broader sector exposure to multiomics and immunodiagnostics, these stocks offer insights into life sciences stock comparison and market positioning.
AZTA Overview and Recent Performance
Azenta, Inc. (AZTA) is a global provider of life sciences solutions, specializing in cold-chain sample management and multiomics services for pharmaceutical, biotech, and academic institutions. In recent market activity, the stock has faced pressure, dropping approximately 24% in a single session following Q2 FY2026 results announced in early May 2026. Reported revenue reached $145 million, up 1% year-over-year but down 3% organically, missing expectations due to softer North American volumes in multiomics and declines in capital-intensive automated storage systems within sample management solutions.
Sentiment has been influenced by non-cash impairments totaling $149 million on multiomics and sample management assets, alongside lowered FY2026 organic revenue guidance to -2% to +1%. Adjusted EBITDA margin contracted to 5.4%, reflecting gross margin pressures and rework costs. Despite challenges, Azenta maintains a strong balance sheet with $565 million in cash and no debt, supporting operational fixes like the Azenta Business System and leadership changes. Year-to-date, shares are down about 26%, underperforming broader indices amid capital equipment spending caution.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY), formerly PerkinElmer's life sciences and diagnostics arm, delivers health science solutions including instruments, reagents, software, and services for discovery, development, and diagnostics. Recent performance has shown resilience, with Q1 2026 revenue of $711.1 million, up 7% reported and 3% organically, surpassing consensus estimates. Adjusted EPS rose 5% to $1.06, driven by strength in diagnostics (reproductive health, immunodiagnostics) and software, despite China-related divestiture plans.
Life sciences grew modestly at 3% organically, with high-margin Signals SaaS (subscriptions as a service) expanding nearly 40% in annual recurring revenue. Management noted improving end-market signals, though Q2 software revenue is projected to decline 20%. The company ended the quarter with solid free cash flow generation and continues capital returns via share repurchases. Shares have declined about 10% year-to-date, reflecting broader sector pressures but buoyed by earnings beats. Recent weeks saw gains post-earnings, highlighting relative stability versus peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, selected from hundreds available that trade thousands of tickers across stocks, ETFs, and crypto. Tickeron offers over 350 AI Trading Bots in total, employing diverse strategies like momentum, sector rotation, price action analysis, and multi-agent systems with risk controls such as take-profit/stop-loss corridors (e.g., TP 3%/SL 2%). Timeframes vary from 5 minutes to 60 minutes, catering to intraday to swing trading styles. The trending section highlights 25 bots best suited to current market conditions, with impressive stats including annualized returns up to +169%, win rates of 51-88%, and profit factors ranging from 1.5 to 11.7. Examples include "Semi Boom Gains Momentum" (+83% annualized, 68% win rate in semiconductors) and volatility bots in nuclear/data centers (+169% annualized). These bots demonstrate adaptability across sectors like tech, industrials, and leveraged ETFs. Investors can review detailed backtests and copy trades via Tickeron's brokerage integration for data-driven strategies.
Head-to-Head Comparison
Azenta (AZTA) and Revvity (RVTY) both serve the life sciences ecosystem but diverge in business models: AZTA focuses on sample storage/management (prone to capital budget cycles) and multiomics services, while RVTY balances life sciences tools with diagnostics (reagents, screening) and high-margin software for recurring stability.
Growth drivers contrast sharply—RVTY's 3% organic growth reflects diagnostics resilience and SaaS expansion, versus AZTA's contraction from volume softness. Recent momentum favors RVTY post-earnings gains, while AZTA contends with impairments and guidance cuts. Risk factors include AZTA's execution gaps in automated systems and North America exposure, against RVTY's China divestiture and macro/FX volatility. Sector-wise, both tap biopharma but RVTY (~$11B market cap, $2.9B revenue) offers scale over AZTA (~$1.1B cap, ~$600M revenue). Market sentiment leans toward RVTY's consistency amid relative performance trade-offs.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors Revvity (RVTY) over Azenta (AZTA), based on superior trend consistency in recent quarters, stable organic growth, and resilient diagnostics/software segments providing downside protection. RVTY's earnings beats and higher recurring revenue position it better amid life sciences caution, while AZTA's impairments and lowered guidance signal elevated near-term risks. Probabilistic edge to RVTY for momentum traders, though both warrant monitoring for catalysts like biopharma spending recovery.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTA is a Hold and RVTY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green whileRVTY’s FA Score has 1 green FA rating(s).
- AZTA’s FA Score: 0 green, 5 red.
- RVTY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 5 TA indicator(s) are bullish while RVTY’s TA Score has 6 bullish TA indicator(s).
- AZTA’s TA Score: 5 bullish, 5 bearish.
- RVTY’s TA Score: 6 bullish, 5 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а -26.18% price change this week, while RVTY (@Medical Specialties) price change was +14.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.08%. For the same industry, the average monthly price growth was +3.59%, and the average quarterly price growth was +23.30%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.85%. For the same industry, the average monthly price growth was +2.49%, and the average quarterly price growth was -7.30%.
Reported Earning Dates
AZTA is expected to report earnings on Aug 11, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.08% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+0.85% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| AZTA | RVTY | AZTA / RVTY | |
| Capitalization | 886M | 11.1B | 8% |
| EBITDA | 36.6M | 766M | 5% |
| Gain YTD | -46.001 | 2.416 | -1,904% |
| P/E Ratio | 42.43 | 47.67 | 89% |
| Revenue | 596M | 2.86B | 21% |
| Total Cash | 381M | N/A | - |
| Total Debt | 55.7M | 3.4B | 2% |
AZTA | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 88 | |
PRICE GROWTH RATING 1..100 | 89 | 48 | |
P/E GROWTH RATING 1..100 | 85 | 32 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (52) in the Medical Specialties industry is in the same range as AZTA (67) in the Electronic Production Equipment industry. This means that RVTY’s stock grew similarly to AZTA’s over the last 12 months.
RVTY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that RVTY’s stock grew similarly to AZTA’s over the last 12 months.
RVTY's SMR Rating (88) in the Medical Specialties industry is in the same range as AZTA (93) in the Electronic Production Equipment industry. This means that RVTY’s stock grew similarly to AZTA’s over the last 12 months.
RVTY's Price Growth Rating (48) in the Medical Specialties industry is somewhat better than the same rating for AZTA (89) in the Electronic Production Equipment industry. This means that RVTY’s stock grew somewhat faster than AZTA’s over the last 12 months.
RVTY's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for AZTA (85) in the Electronic Production Equipment industry. This means that RVTY’s stock grew somewhat faster than AZTA’s over the last 12 months.
| AZTA | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 61% |
| Advances ODDS (%) | 5 days ago 70% | 7 days ago 66% |
| Declines ODDS (%) | 14 days ago 82% | 14 days ago 66% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 80% | 2 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MYSPX | 78.67 | 0.15 | +0.19% |
| NYLI S&P 500 Index Investor Class | |||
| CYPIX | 77.19 | N/A | N/A |
| ProFunds Consumer Disctnry Ultra Sec Inv | |||
| LICYX | 21.02 | N/A | N/A |
| Lord Abbett International Equity I | |||
| IRFAX | 9.47 | N/A | N/A |
| Cohen & Steers International Realty A | |||
| BBTLX | 17.80 | -0.02 | -0.11% |
| Bridge Builder Tax Managed Large Cap | |||
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with XRAY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | -6.56% | ||
| XRAY - AZTA | 63% Loosely correlated | -0.82% | ||
| IQV - AZTA | 60% Loosely correlated | -2.89% | ||
| RVTY - AZTA | 59% Loosely correlated | -2.03% | ||
| A - AZTA | 59% Loosely correlated | -3.60% | ||
| MTD - AZTA | 59% Loosely correlated | -4.08% | ||
More | ||||